Neuphoria Therapeutics Inc (NEUP) Ownership
NEUP ownership summary
as of October 18, 2026- Institutions
- 42.8% of shares outstanding
- Insiders
- 5.02% of shares outstanding
- Shares outstanding
- 5.4M
- Float
- 5.4M shares available to trade
- Short interest
- 0.45% 20K shares short
- Days to cover
- 1.11 short interest down 19.0% vs prior month
- Institutions 42.85%
- Insiders 5.02%
- Other investors 52.13%
NEUP top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management, LP | 16.18% | 875K | $2.9M | — | June 30, 2026 |
| 2 | AdvisorShares Investments, LLC | 4.67% | 253K | $834,600 | +97,542 (+62.8%) | June 30, 2026 |
| 3 | Vanguard Capital Management, LLC | 3.21% | 173K | $572,510 | +74,972 (+76.1%) | June 30, 2026 |
| 4 | Shay Capital LLC | 2.88% | 156K | $514,213 | +4,812 (+3.2%) | June 30, 2026 |
| 5 | Balyasny Asset Management LLC | 2.63% | 142K | $469,352 | +45 (+0.0%) | June 30, 2026 |
| 6 | Citadel Advisors Llc | 1.34% | 73K | $239,445 | +53,228 (+275.4%) | June 30, 2026 |
| 7 | Geode Capital Management, LLC | 0.92% | 50K | $163,403 | −2,491 (−4.8%) | June 30, 2026 |
| 8 | Ikarian Capital, LLC | 0.88% | 47K | $156,562 | — | June 30, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 0.62% | 34K | $111,560 | +217 (+0.6%) | June 30, 2026 |
| 10 | ADAR1 Capital Management LLC | 0.55% | 30K | $99,000 | — | June 30, 2026 |
| 11 | Renaissance Technologies Corp | 0.47% | 26K | $84,150 | +25,500 (0.0%) | June 30, 2026 |
| 12 | XTX Topco Ltd | 0.43% | 23K | $76,194 | +23,089 (0.0%) | June 30, 2026 |
| 13 | HRT FINANCIAL LLC | 0.42% | 23K | $75,454 | +22,865 (0.0%) | June 30, 2026 |
| 14 | Jane Street Group LLC | 0.28% | 15K | $49,180 | +14,903 (0.0%) | June 30, 2026 |
| 15 | BOOTHBAY FUND MANAGEMENT, LLC | 0.26% | 14K | $46,200 | — | June 30, 2026 |
| 16 | Commonwealth Equity Services, LLC | 0.21% | 11K | $37,033 | — | June 30, 2026 |
| 17 | Northern Trust Corp | 0.20% | 11K | $35,013 | +10,610 (0.0%) | June 30, 2026 |
| 18 | Merck & Co Inc | 0.19% | 10K | $33,089 | — | June 30, 2026 |
| 19 | UBS Group AG | 0.04% | 2,117 | $6,986 | −199 (−8.6%) | June 30, 2026 |
| 20 | Morgan Stanley - Brokerage Accounts | <0.01% | 58 | $191 | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 11 holders added 328K shares and 2 cut 2,690.
NEUP top mutual fund and ETF holders
6 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | AdvisorShares Psychedelics ETF | 5.78% | 313K | $1.0M | — | September 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.04% | 110K | $363,564 | — | August 31, 2026 |
| 3 | Fidelity Extended Market Index | 0.70% | 38K | $124,476 | +9,671 (+34.5%) | August 31, 2026 |
| 4 | Fidelity Series Total Market Index | 0.15% | 8,036 | $26,519 | — | August 31, 2026 |
| 5 | Fidelity Total Market Index | 0.10% | 5,396 | $17,807 | +3,395 (+169.7%) | August 31, 2026 |
| 6 | Fidelity Nasdaq Composite Index | 0.04% | 2,427 | $8,009 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
NEUP insider transactions
latest 1| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-21 | Lynx1 Capital Management Lp | Buy | $5.14 | 639,110 | $3.3M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
NEUP shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns NEUP
Institutional investors own 42.8% of Neuphoria Therapeutics's shares and insiders 5.02%. The largest holder is Lynx1 Capital Management, LP with 16.18% of the shares (875K), as of June 30, 2026. Among the top 20 institutions, 11 added shares and 2 reduced their stake in the latest filings. Short interest is 0.45% of the float, or 1.11 days of average trading volume. The share count fell 98.9% since 2014.
Related: NEUP analyst forecast, NEUP key metrics. See the NEUP stock overview for the latest quote and news.
NEUP ownership FAQ
Who owns the most Neuphoria Therapeutics stock?
The largest shareholders of Neuphoria Therapeutics are Lynx1 Capital Management, LP (16.18%), AdvisorShares Investments, LLC (4.67%), Vanguard Capital Management, LLC (3.21%), Shay Capital LLC (2.88%), Balyasny Asset Management LLC (2.63%).
What percentage of Neuphoria Therapeutics is owned by institutions?
Institutions hold 42.8% of Neuphoria Therapeutics's shares outstanding; insiders hold 5.02%.
Which funds own Neuphoria Therapeutics?
The largest fund holders of Neuphoria Therapeutics are AdvisorShares Psychedelics ETF (5.78%), Vanguard MStar Total Stk Mkt Idx Invest (2.04%), Fidelity Extended Market Index (0.70%), Fidelity Series Total Market Index (0.15%), Fidelity Total Market Index (0.10%).
What is Neuphoria Therapeutics's short interest?
20K shares of Neuphoria Therapeutics were sold short, 0.45% of the float; at the average daily volume it would take 1.11 days to cover.
Are insiders buying or selling Neuphoria Therapeutics?
Of the latest 1 reported insider transactions in Neuphoria Therapeutics (since October 21, 2025), 1 were purchases and 0 were sales.
How many shares of Neuphoria Therapeutics are outstanding?
Neuphoria Therapeutics has 5.4M shares outstanding, of which 5.4M are in the public float.